Clinigen acquires global rights to Proleukin outside US
Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.
Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.
Takeda Pharmaceutical’s £45.3bn ($62bn) acquisition of Shire has been unconditionally approved by the US Federal Trade Commission (FTC).